Thus, to explore a possible co-targeted therapy of both EGFR and MPS1 for the treatment of HNSCC, we used the UALCAN database to obtain data mainly concerning MPS1 expression and head and neck cancer. This evidence concerns the gene TTK and head and neck cancer.